Biosimilar Insights
-
Serial Success With Triumvira's Rob Williamson
3/10/2024
Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Learn secrets to his serial success on this week's Business of Biotech podcast.
-
Serial Success With Triumvira's Rob Williamson
3/10/2024
Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging around as many successful exits as Williamson has seen, one might become an expert via osmosis. But Williamson isn't passive about honing his vision for progressive therapeutic dealmaking.
-
Exosome Isolation By TFF And Size Exclusion Chromatography
3/6/2024
Here, we demonstrate a scalable workflow for the isolation of exosomes that combines tangential flow filtration for the concentration of exosomes followed by gentle size exclusion chromatography.
-
A Scalable Single-Use Two-Step pDNA Purification Process
3/6/2024
Evaluate the performance of a single-use two-step plasmid purification process, and see how it compares to the existing three-step purification method.
-
High-Titer rAAV Production In Bioreactors Using Producer Cell Lines
3/6/2024
Here, we detail the upstream process development and optimization for an AAV8-GFP proof-of-concept (PoC) producer single cell clone (SCC) in both batch and perfusion modes.
-
Safer AAV Through Reduced Host-Cell DNA Encapsidation
3/6/2024
While most hcDNA molecules outside AAV particles can be eliminated during downstream processing, encapsidated hcDNA molecules remain largely undetectable. Learn how to overcome this critical issue.
-
Producer Cell Line For Large-Scale Viral Vector Manufacturing
3/6/2024
Embrace the future of gene therapies and overcome challenges in large-scale viral vector manufacturing with a one-step process that ensures robustness and scalability.
-
Cost Modeling Comparison Of Bioreactors To Produce Adherent Cell Products
3/6/2024
This study employs BioSolve software, a reference for cost analyses in the biopharmaceutical industry, to compare the upstream manufacturing costs between multitray stacks and the iCELLis™ bioreactor.
-
Demand More From Your Oligo Synthesizer
3/4/2024
The market for oligonucleotide therapeutics is expanding, and the pipeline is diverse. Gain insight into how you can fast-track your molecule's development with verified synthesizers, columns, and scientific support and expertise.
-
Imagine The Future: Enhanced Oligonucleotide Synthesis
3/4/2024
Learn about flexible control software that has revolutionized the way method creation, evaluation, and process optimizations for scale-up are completed.